Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics

Seminars in Cancer Biology

Volumn 23, Issue 6 PB, 2013, Pages 553-560

  Yu, Le ^a   Liu, Shuwen ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Autophagy; Bcl 2 family; BH3 mimetics; Cancer therapy

Indexed keywords

3 METHYLADENINE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BECLIN 1; BH3 PROTEIN; CHLOROQUINE; DEXAMETHASONE; GOSSYPOL; HYDROXYCHLOROQUINE; ISOSORBIDE; LAPATINIB; NAVITOCLAX; OBATOCLAX; PROTEIN BCL 2;

APOPTOSIS; AUTOPHAGY; CELL DEATH; CELL FATE; DIGESTIVE SYSTEM CANCER; DRUG CYTOTOXICITY; DRUG INTERACTION; DRUG MECHANISM; HUMAN; MITOCHONDRIAL PERMEABILITY; NECROPTOSIS; NONHUMAN; PROTEIN FUNCTION; REVIEW;

APOPTOSIS; AUTOPHAGY; BCL-2 FAMILY; BH3 MIMETICS; CANCER THERAPY;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; GASTROINTESTINAL NEOPLASMS; HUMANS; MOLECULAR MIMICRY; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; SULFONAMIDES;

EID: 84887616429     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.08.008     Document Type: Review

References (103)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2000, 100:57-70.
2. Fulda S. Tumor resistance to apoptosis. International Journal of Cancer 2009, 124:511-515.
3. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
4. Youle R.J., Strasser A. The Bcl-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology 2008, 9:47-59.
5. Buggins A.G., Pepper C.J. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leukemia Research 2010, 34:837-842.
6. Yang E., Korsmeyer S.J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996, 88:386-401.
7. Coultas L., Strasser A. The role of the Bcl-2 protein family in cancer. Seminars in Cancer Biology 2003, 13:115-123.
8. Letai A.G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nature Reviews Cancer 2008, 8:121-132.
9. Zhang L., Ming L., Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resistance Updates 2007, 10:207-217.
10. Nakatogawa H., Suzuki K., Kamada Y., Ohsumi Y. Dynamics and diversity in autophagy mechanisms: lessons from yeast. Nature Reviews Molecular Cell Biology 2009, 10:458-467.
11. Shimizu S., Kanaseki T., Mizushima N., Mizuta T., Arakawa-Kobayashi S., Thompson C.B., et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Natural Cell Biology 2004, 6:1221-1228.
12. Lum J.J., Bauer D.E., Kong M., Harris M.H., Li C., Lindsten T., et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005, 120:237-248.
13. Gonzalez-Polo R.A., Boya P., Pauleau A.L., Jalil A., Larochette N., Souquere S., et al. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. Journal of Cell Science 2005, 118:3091-3102.
14. Qiao L., Wong B.C. Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drugs Resistance Updates 2009, 12:55-64.
15. de Bono J.S., Rowinsky E.K. Therapeutics targeting signal transduction for patients with colorectal carcinoma. British Medical Bulletin 2002, 64:227-254.
16. Jin-Song Y., Zhao-Xia W., Cheng-Yu L., Xiao-Di L., Ming S., Yuan-Yuan G., et al. Prognostic significance of Bcl-xL gene expression in human colorectal cancer. Acta Histochemical 2011, 113:810-814.
17. Wilson J.W., Nostro M.C., Balzi M., Faraoni P., Cianchi F., Becciolini A., et al. Bcl-w expression in colorectal adenocarcinoma. British Journal of Cancer 2000, 82:178-185.
18. Backus H.H., Van Groeningen C.J., Vos W., Dukers D.F., Bloemena E., Wouters D., et al. Differential expression of cell cycle and apoptosis relate proteins in colorectal mucosa, primary colon tumours, and liver metastases. Journal of Clinical Pathology 2002, 55:206-211.
19. Kim M.R., Jeong E.G., Chae B., Lee J.W., Soung Y.H., Nam S.W., et al. Pro-apoptotic PUMA and anti-apoptotic phosphor-BAD are highly expressed in colorectal carcinomas. Digestive Diseases and Sciences 2007, 52:2751-2756.
20. Lee J.W., Soung Y.H., Kim S.Y., Nam S.W., Kim C.J., Cho Y.G., et al. Inactivating mutations of proapoptotic Bad gene in human colon cancers. Carcinogenesis 2004, 15:1371-1376.
21. Ionov Y., Yamamoto H., Krajewski S., Reed J.C., Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:10872-10877.
22. Nehls O., Hass H.G., Okech T., Zenner S., Hsieh C.J., Sarbia M., et al. Prognostic implications of BAX protein expression and microsatellite instability in all non-metastatic stages of primary colon cancer treated by surgery alone. International Journal of Colorectal Disease 2009, 24:655-663.
23. Azmi S., Dinda A.K., Chopra P., Chattopadhyay T.K., Singh N. Bcl-2 expression is correlated with low apoptotic index and associated with histopathological grading in esophageal squamous cell carcinoma. Tumor Biology 2000, 21:3-10.
24. Kang S.Y., Han J.H., Lee K.J., Choi J.H., Park J.I., Kim H.I., et al. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treatment with definitive chemotherapy. Clinical Cancer Research 2007, 13:4146-4153.
25. van der Woude C.J., Jansen P.L., Tiebosch A.T., Beuving A., Homan M., Kleibeuker J.H., et al. Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype. Human Pathology 2002, 33:686-692.
26. Sasatomi E., Tokunaga O., Miyazaki K. Spontaneous apoptosis in gallbladder carcinoma. Relationships with clinicapathologic factors, expression of E-cadherin, bcl-2 protooncogene, and p53 oncosuppressor gene. Cancer 1996, 78:2101-2110.
27. Zhang M., Pan J.W., Ren T.R., Zhu Y.F., Han Y.J., Kuhnel W. Correlated expression of inducible nitric oxide synthase and P53, Bax in benign and malignant diseased gallbladder. Annals of Anatomy 2003, 185:549-554.
28. Likui W., Qun L., Wangqing Z., Haifeng S., Fangqiu L., Xiaojun L. Prognostic role of myeloid cell leukemia-1 protein (Mcl-1) expression in human gastric cancer. Journal of Surgical Oncology 2009, 100:396-400.
29. Lee H.W., Lee S.S., Lee S.J., Um H.D. Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation. Cancer Research 2003, 63:1093-1100.
30. Jeong S.H., Han J.H., Kim J.H., Ahn M.S., Hwang Y.H., Lee H.W., et al. Bax predicts outcome in gastric cancer patients treated with 5-fluorouacil, leucovorin, and oxaliplatin palliative chemotherapy. Digestive Disease and Sciences 2011, 56:131-138.
31. Mrozek A., Petrowsky H., Stum I., Kraus J., Hermann S., Hauptmann S., et al. Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability. Cell Death and Differentiation 2003, 10:461-467.
32. Karamitopoulou E., Tornillo L., Zlobec I., Cioccari L., Carafa V., Borner M., et al. Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. American Journal of Clinical Pathology 2008, 130:780-786.
33. Watanabe J., Kushihata F., Honda K., Sugita A., Tateishi N., Mominoki K., et al. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 2004, 135:604-612.
34. Fleischer B., Schulze-Bergkamen H., Schuchmann M., Weber A., Biesterfeld S., Muller M., et al. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. International Journal of Oncology 2006, 28:25-32.
35. Sun C.Y., Wang B.L., Hu C.Q., Peng R.Y., Gao Y.B., Gu Q.Y., et al. Expression of the Bcl-2 gene and its significance in human pancreatic carcinoma. Hepatobiliary & Pancreatic Diseases International 2002, 1:306-308.
36. Magistrelli P., Coppola R., Tonini G., Vincenzi B., Santini D., Borzomati D., et al. Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. Journal of Cellular Biochemistry 2006, 97:98-108.
37. Friess H., Lu Z., Graber H.U., Zimmermann A., Adler G., Korc M., et al. bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 1998, 43:414-421.
38. Goldstein J.C., Waterhouse N.J., Juin P., Evan G.I., Green D.R. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Natural Cell Biology 2000, 2:156-162.
39. Sasi N., Hwang M., Jaboin J., Csiki I., Lu B. Regulated cell death pathway: new twists in modulation of BCL2 family function. Molecular Cancer Therapeutics 2009, 8:1421-1429.
40. Lindsten T., Ross A.J., King A., Zong W., Rathmell J.C., Shiels H.A., et al. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Molecular Cell 2000, 6:1389-1399.
41. Kvansakul M., Yang H., Fairlie W.D., Czabotar P.E., Fischer S.F., Perugini M.A., et al. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimmer that binds a highly selective subset of BH3-containing death ligands. Cell Death and Differentiation 2008, 15:1564-1571.
42. Cory S., Adams J.M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nature Reviews Cancer 2002, 2:647-656.
43. Sattler M., Liang H., Nettesheim D., Meadows R.P., Harlan J.E., Eberstadt M., et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997, 275:983-986.
44. Letai A., Bassik M., Walensky L.D., Sorcinelli M.D., Weiler S., Korsmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2:183-192.
45. Gavathiotis E., Suzuki M., Davis M.L., Pitter K., Bird G.H., Katz S.G., et al. BAX activation is initiated at a novel interaction site. Nature 2008, 455:1076-1081.
46. Puthalakath H., Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death and Differentiation 2002, 9:505-512.
47. Strasser A., Cory S., Adams J.M. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO Journal 2011, 30:3667-3683.
48. Kim H., Rafiuddin-Shah M., Tu H.C., Jeffers J.R., Zambetti G.P., Hsieh J.J., et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nature Cell Biology 2006, 8:1348-1358.
49. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecular Cell 2005, 17:393-403.
50. Willis S.N., Fletcher J.I., Kaufmann T., van Delft M.F., Chen L., Czabotar P.E., et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007, 315:856-859.
51. Leber B., Geng F., Kale J., Andrews D.W. Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Reviews in Molecular Medicine 2010, 12:e28.
52. Zhou F., Yang Y., Xing D. Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS Journal 2011, 278:403-413.
53. Levine B., Sinha S., Kroemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 2008, 4:600-606.
54. Kihara A., Kabeya Y., Ohsumi Y., Yoshimori T. Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Reports 2001, 2:330-335.
55. Liang X.H., Kleeman L.K., Jiang H.H., Gordon G., Goldman J.E., Berry G., et al. Protection against fatal sindbis virus encephalitis by Beclin, a novel Bcl-2-interacting protein. Journal of Virology 1998, 72:8586-8596.
56. Maiuri M.C., Criollo A., Tasdemir E., Vicencio J.M., Tajeddine N., Hickman J.A., et al. BH3-only proteins and BH3 Mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy 2007, 3:374-376.
57. Erlich S., Mizrachy L., Segev O., Lindenbiom L., Zmira O., Adi-Harel S., et al. Differential interactions between Beclin 1 and Bcl-2 family members. Autophagy 2007, 3:561-568.
58. Pattingre S., Tassa A., Qu X., Garuti R., Liang X.H., Mizushima N., et al. Bcl-2 anti-apoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927-939.
59. Rashmi R., Pillai S.G., Vijayalingam S., Ryerse J., Chinnadurai G. BH3-only protein BIK induces caspase-independent cell death with autophagic features in Bcl-2 null cells. Oncogene 2008, 27:1366-1375.
60. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nature Reviews Drug Discovery 2010, 9:447-464.
61. Bajwa N., Liao C., Nikolovska-Coleska Z. Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. Expert Opinion on Therapeutic Patents 2012, 22:37-55.
62. Liu Q., Wang H.G. Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors. Communicative & Integrative Biology 2012, 5:557-565.
63. Davids M.S., Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. Journal of Clinical Oncology 2012, 30:3127-3135.
64. Azmi A.S., Wang Z., Philip P.A., Mohammad R.M., Sarkar F.H. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opinion on Emerging Drugs 2011, 16:59-70.
65. Joudeh J., Claxton D. Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms. Expert Opinion on Investigational Drugs 2012, 21:363-373.
66. Zhai D., Jin C., Satterthwait A.C., Reed J.C. Comparison of chemical inhibitors of anti-apoptotic Bcl-2-family proteins. Cell Death and Differentiation 2006, 13:1419-1421.
67. Bonapace L., Bornhauser B.C., Schmitz M., Cario G., Ziegler U., Niggli F.K., et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. Journal of Clinical Investigation 2012, 120:1310-1323.
68. Sharma A., Singh K., Mazumder S., Hill B.T., Kalaycio M., Almasan A. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells. Cell Death and Disease 2013, 4:e628.
69. Tang Y., Hamed H.A., Cruickshanks N., Fisher P.B., Grant S., Dent P. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Molecular Pharmacology 2012, 81:527-540.
70. Heidari N., Hicks M.A., Harada H. G.X15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death and Disease 2010, 1:e76.
71. McCoy F., Hurwitz J., McTavish N., Paul I., Barnes C., O'Hagan B., et al. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death and Disease 2010, 1:e108.
72. Basit F., Cristofanon S., Fulda S. Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosoml membranes. Cell Death and Differentiation 2013, 10.1038/cdd.2013.45.
73. Martin A.P., Mitchell C., Rahmani M., Nephew K.P., Grant S., Dent P. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biology and Therapy 2009, 8:2084-2096.
74. Martin A.P., Park M.A., Mitchell C., Walker T., Rahmani M., Thorburn A., et al. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Molecular Pharmacology 2009, 76:327-341.
75. Wei Y., Kadia T., Tong W., Zhang M., Jia Y., Yang H., et al. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and antophagy. Autophagy 2010, 6:976-978.
76. Wei Y., Kadia T., Tong W., Zhang M., Jia Y., Yang H., et al. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clinical Cancer Research 2010, 16:3923-3932.
77. Brem E.A., Thudium K., Khubchandani S., Tsai P.C., Olejniczak S.H., Bhat S., et al. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. British Journal of Haematology 2011, 153:599-611.
78. Pan J., Cheng C., Verstovsek S., Chen Q., Jin Y., Cao Q. The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Letters 2010, 293:167-174.
79. Schwartz-Roberts J.L., Shajahan A.N., Cook K.L., Warri A., Abu-Asab M., Clarke R. G.X15-070 (obatoclax) induces apoptosis and inhibits cathepsin d- and l-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells. Molecular Cancer Therapeutics 2013, 12:448-459.
80. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
81. Kaminskyy V., Zhivotovsky B. Proteases in autophagy. Biochimica et Biophysica Acta 2012, 1824:44-50.
82. Zhang L., Yu J., Pan H., Hu P., Hao Y., Cai W., et al. Small molecule regulators of autophagy identified by an image-based high throughput screen. Proceedings of the National Academy of Sciences of the United States of America 2007, 16:2617-2628.
83. Lessene G., Czabotar P.E., Colman P.M. BCL-2 family antagonists for cancer therapy. Nature Reviews Drug Discovery 2008, 7:989-1000.
84. Kang M.H., Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clinical Cancer Research 2009, 15:1126-1132.
85. Gao P., Bauvy C., Souquere S., Tonelli G., Liu L., Zhu Y., et al. The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin-1-dependen and Beclin-1-independent cytoprotective autophagy in cancer cells. Journal of Biological Chemistry 2010, 285:25570-25581.
86. Lian J., Karnak D., Xu L. The Bcl-2-Beclin 1 interaction in (-)-gossypol-induced autophagy versus apoptosis in prostate cancer cells. Autophagy 2010, 6:1201-1203.
87. Lian J., Wu X., He F., Karnak D., Tang W., Meng Y., et al. A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death and Differentiation 2011, 18:60-71.
88. Ni Z., Dai X., Wang B., Ding W., Cheng P., Xu L., et al. Natural Bcl-2 inhibitor (-)-gossypol induces protective autophagy via reactive oxygen species-high mobility group box 1 pathway in Burkitt lymphoma. Leukemia and Lymphoma 2013, [Epub ahead of print].
89. Kang R., Livesey K.M., Zeh H.J., Lotze M.T., Tang D. HMGB1 as an autophagy sensor in oxidative stress. Autophagy 2011, 7:904-908.
90. Voss V., Senft C., Lang V., Ronellenfitsch M.W., Steinbach J.P., Seifert V., et al. The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Molecular Cancer Research 2010, 8:1002-1016.
91. Gump J.M., Thorburn A. Autophagy and apoptosis: what is the connection. Trends Cell in Biology 2011, 21:387-392.
92. Shen H.M., Codogno P. Autophagy is a survival force via suppression of necrotic cell death. Experimental Cell Research 2012, 318:1304-1308.
93. Wu Y.T., Tan H.L., Huang Q., Ong C.N., Shen H.M. Activation of the PI3K-Akt-mTOR signaling pathway promotes necrotic cell death via suppression of autophagy. Autophagy 2009, 5:824-834.
94. Wu Y.T., Tan H.L., Huang Q., Kim Y.S., Pan N., Ong W.Y., et al. Autophagy plays a protective role during zVAD-induced necrotic cell death. Autophagy 2008, 4:457-466.
95. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
96. Maiuri M.C., Le Toumelin G., Criollo A., Rain J.C., Gautier F., Juin P., et al. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO Journal 2007, 26:2527-2539.
97. Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nature Reviews Molecular Cell Biology 2007, 8:741-752.
98. Malik S.A., Orhon I., Morselli E., Criollo A., Shen S., Marino G., et al. BH3 mimetics activate multiple pro-autophagic pathways. Oncogene 2011, 30:3918-3929.
99. Saleem A., Dvorzhinski D., Santanam U., Mathew R., Bray K., Stein M., et al. Effect of dual inhibition of apoptosis and autophagy in prostate cancer. Prostate 2012, 72:1374-1381.
100. Armstrong J.L., Corazzari M., Martin S., Pagliarini V., Falasca L., Hill D.S., et al. Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition. Clinical Cancer Research 2011, 17:2216-2226.
101. Samuel S., Beljanski V., Van Grevenynghe J., Richards S., Ben Yebdri F., He Z., et al. BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis. Molecular Therapy 2013, 21:1413-1423.
102. Zinn R.L., Gardner E.E., Dobromilskaya I., Murphy S., Marchionni L., Hann C.L., et al. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer. Molecular Cancer 2013, 12(16). 10.1186/1476-4598-12-16.
103. Wu W.K., Coffelt S.B., Cho C.H., Wang X.J., Lee C.W., Chan F.K., et al. The autophagic paradox in cancer therapy. Oncogene 2012, 31:939-953.